JS
CERO

Jeffrey Smith’s CERo Therapeutics CERO Stock Holding History

Jeffrey Smith’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11
Closed -$215K – 156
2022
Q3 		$215K Hold
11
– – ﹤0.01% 175
2022
Q2 		$213K Hold
11
– – ﹤0.01% 181
2022
Q1 		$213K Sell
11
-1
-8% -$19.9K ﹤0.01% 169
2021
Q4 		$238K Buy
+12
New +$238K ﹤0.01% 136

Other funds holding CERO

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return

Jeffrey Smith's CERO Position: Q4 2022 in Review

Jeffrey Smith sold out of CERo Therapeutics (CERO) in Q4 2022, closing a stake of 11 shares — an estimated $215K sold.

Jeffrey Smith first reported a position in CERO in Q4 2021 and held it in 4 quarters. The position peaked at $238K in Q4 2021. 45 funds tracked by Wall St. Rank hold CERO as of Q4 2022.

  • Jeffrey Smith reported no remaining CERo Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jeffrey Smith sold 11 CERo Therapeutics shares in Q4 2022, an estimated $215K.
  • Jeffrey Smith first reported a position in CERo Therapeutics in Q4 2021 and held it in 4 quarters.
  • Jeffrey Smith's CERo Therapeutics position peaked at $238K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2022.

Based on Starboard Value's 13F filing for Q4 2022, filed 14 Feb 2023.